Effect of Plasmapheresis on the Efficacy of Rituximab in Antibody-Mediated Rejection Patients
Authors:
- 20 February 2024
- journal article
- research article
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (3) , 723-725
Abstract
No abstract availableKeywords
Funding Information
- Inha University
This publication has 9 references indexed in Scilit:
- Current status of the evaluation and management of antibody-mediated rejection in kidney transplantationCurrent Opinion in Nephrology and Hypertension, 2015
- Indicators of Treatment Responsiveness to Rituximab and Plasmapheresis in Antibody-Mediated Rejection After Kidney TransplantationTransplantation, 2015
- Review of Bortezomib Treatment of Antibody-Mediated Rejection in Renal TransplantationAntioxidants & Redox Signaling, 2014
- Antibody‐Mediated Rejection in Kidney Transplantation: A Review of Pathophysiology, Diagnosis, and Treatment OptionsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
- Rituximab in renal transplantationTransplant International, 2013
- Antibody-mediated rejection in kidney transplantation: an updateExpert Opinion on Pharmacotherapy, 2011
- ABO Antibody Titer and Risk of Antibody‐Mediated Rejection in ABO‐Incompatible Renal TransplantationAmerican Journal of Transplantation, 2010
- Long-Term Experience of Plasmapheresis in Antibody-Mediated Rejection in Renal TransplantationTransplantation Proceedings, 2009
- The Impact of Pretransplant Dialysis on Outcomes in Renal TransplantationSeminars in Dialysis, 2005